Infigratinib Phosphate Patent Expiration
Infigratinib Phosphate was first introduced by Helsinn Healthcare Sa
Infigratinib Phosphate Patents
Given below is the list of patents protecting Infigratinib Phosphate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Truseltiq | US10278969 | Pharmaceutical dosage forms | Dec 11, 2034 | Helsinn Hlthcare |
| Truseltiq | US11160804 | Pharmaceutical dosage forms | Dec 11, 2034 | Helsinn Hlthcare |
| Truseltiq | US8552002 | Compounds and compositions as protein kinase inhibitors | Aug 25, 2029 | Helsinn Hlthcare |
| Truseltiq | US9067896 | Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl) -phenylamino]-pyrimidin-4-yl}-1-methyl-urea and salts thereof | Aug 06, 2028 | Helsinn Hlthcare |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Infigratinib Phosphate's patents.
Latest Legal Activities on Infigratinib Phosphate's Patents
Given below is the list recent legal activities going on the following patents of Infigratinib Phosphate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Miscellaneous Incoming Letter | 23 May, 2024 | US8552002 |
| Letter from FDA or Dept of Agriculture re PTE application | 16 May, 2024 | US8552002 |
| transaction for FDA Determination of Regulatory Review Period | 18 Jan, 2024 | US8552002 |
| transaction for FDA Determination of Regulatory Review Period | 07 Dec, 2023 | US8552002 |
| Second letter to regulating agency to determine regulatory review period | 09 Mar, 2023 | US8552002 |
| Letter from FDA or Dept of Agriculture re PTE application | 18 Jan, 2023 | US8552002 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 30 Dec, 2022 | US9067896 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 07 Nov, 2022 | US10278969 |
| Initial letter Re: PTE Application to regulating agency | 28 Jan, 2022 | US8552002 |
| Patent Issue Date Used in PTA Calculation Critical | 02 Nov, 2021 | US11160804 |
Infigratinib Phosphate's Family Patents
